RxDoctor Payments Data

Dana Cochrane-Hoekstra

Physician Assistant · Norton Shores, MINPI 1295749463

Payments from drug & device makers

$12,629in general payments, 2019–2025

Across 891 payments — averaging $14.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Alkermes, Inc.$790
  • Otsuka America Pharmaceutical, Inc.$757
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$12,568100%
  • Education$610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,629 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$7,949
Medicare patients
27
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine25$381,861
AustedoDeutetrabenazine11$171,543
RexultiBrexpiprazole42$85,002
CaplytaLumateperone Tosylate20$32,394
TrintellixVortioxetine Hydrobromide44$29,591
VraylarCariprazine Hcl13$17,804
VyvanseLisdexamfetamine Dimesylate29$15,446
Lisdexamfetamine Dimesylate20$3,886
Desvenlafaxine Succinate ErDesvenlafaxine Succinate73$3,774
Paliperidone ErPaliperidone25$3,559
Venlafaxine Hcl ErVenlafaxine Hcl34$2,750
Lamotrigine89$2,400
Doxepin Hcl48$2,102
Duloxetine Hcl38$1,944
Asenapine Maleate12$1,822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$1,317$553,40436 claims
Otsuka America Pharmaceutical, Inc.Rexulti$757$85,00242 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$216$45,03873 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$2,158$32,39420 claims
AbbVieVraylar$1,890$17,80413 claims
Lilly USA, LLCOlanzapine$70$1,42570 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Norton Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →